EGI
MCRB icon

EAM Global Investors’s Seres Therapeutics MCRB Stock Holding History

EAM Global Investors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,081
Closed -$3.44M – 159
2020
Q3 		$3.44M Buy
+6,081
New +$2.02M 1.26% 16

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

EAM Global Investors's MCRB Position: Q4 2020 in Review

EAM Global Investors sold out of Seres Therapeutics (MCRB) in Q4 2020, closing a stake of 6,081 shares — an estimated $3.44M sold.

EAM Global Investors first reported a position in MCRB in Q3 2020 and held it in 1 quarter. The position peaked at $3.44M in Q3 2020. 152 funds tracked by Wall St. Rank hold MCRB as of Q4 2020.

  • EAM Global Investors reported no remaining Seres Therapeutics position as of Q4 2020 after selling out during the quarter.
  • EAM Global Investors sold 6,081 Seres Therapeutics shares in Q4 2020, an estimated $3.44M.
  • EAM Global Investors first reported a position in Seres Therapeutics in Q3 2020 and held it in 1 quarter.
  • EAM Global Investors's Seres Therapeutics position peaked at $3.44M in Q3 2020.
  • 152 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2020.

Based on EAM Global Investors's 13F filing for Q4 2020, filed 11 Feb 2021.